Global GLP-1 Drug Peptide API Supply, Demand and Key Producers, 2023-2029

Global GLP-1 Drug Peptide API Supply, Demand and Key Producers, 2023-2029

The global GLP-1 Drug Peptide API market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

GLP-1 (Glucagon-Like Peptide-1) drugs are a class of drugs used to treat type 2 diabetes and obesity, usually prepared in the form of polypeptides. These drugs mimic the GLP-1 hormone in the body, causing the release of insulin and controlling blood sugar levels. Peptide APIs are the starting components of these drugs, typically synthesized or produced in laboratories and used in further formulation preparations.

This report studies the global GLP-1 Drug Peptide API production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for GLP-1 Drug Peptide API, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Drug Peptide API that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global GLP-1 Drug Peptide API total production and demand, 2018-2029, (Tons)

Global GLP-1 Drug Peptide API total production value, 2018-2029, (USD Million)

Global GLP-1 Drug Peptide API production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (Tons)

Global GLP-1 Drug Peptide API consumption by region & country, CAGR, 2018-2029 & (Tons)

U.S. VS China: GLP-1 Drug Peptide API domestic production, consumption, key domestic manufacturers and share

Global GLP-1 Drug Peptide API production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (Tons)

Global GLP-1 Drug Peptide API production by Type, production, value, CAGR, 2018-2029, (USD Million) & (Tons)

Global GLP-1 Drug Peptide API production by Application production, value, CAGR, 2018-2029, (USD Million) & (Tons).

This reports profiles key players in the global GLP-1 Drug Peptide API market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CPC Scientific, Novo Nordisk, Teva Pharmaceutical Industries Ltd, JYMedtech, Zhejiang Peptites Biotech, Shengnuo Biotechnology, Suzhou Tianma Pharmaceutical, SINOPEP and WuXi AppTec, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Drug Peptide API market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Tons) and average price (US$/Ton) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global GLP-1 Drug Peptide API Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global GLP-1 Drug Peptide API Market, Segmentation by Type
Semaglutide
Liraglutide
Tilpotide

Global GLP-1 Drug Peptide API Market, Segmentation by Application
Diabetes
Obesity
Other

Companies Profiled:
CPC Scientific
Novo Nordisk
Teva Pharmaceutical Industries Ltd
JYMedtech
Zhejiang Peptites Biotech
Shengnuo Biotechnology
Suzhou Tianma Pharmaceutical
SINOPEP
WuXi AppTec
HYBIO Pharmaceutical

Key Questions Answered

1. How big is the global GLP-1 Drug Peptide API market?

2. What is the demand of the global GLP-1 Drug Peptide API market?

3. What is the year over year growth of the global GLP-1 Drug Peptide API market?

4. What is the production and production value of the global GLP-1 Drug Peptide API market?

5. Who are the key producers in the global GLP-1 Drug Peptide API market?